Double radiation attack may slow tough gut tumors

NCT ID NCT07150546

Recruiting now Disease control Sponsor: Emory University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests whether adding focused external radiation (SBRT) before a standard radioactive drug therapy (177Lu-DOTATATE) is safe and effective for people with large, inoperable neuroendocrine tumors of the digestive system. About 15 adults whose tumors have grown despite prior treatment will receive both therapies. The goal is to see if the combination can better control the disease than the drug alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIGESTIVE SYSTEM NEUROENDOCRINE TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

digestive system neuroendocrine neoplasm digestive system neuroendocrine tumor, grade 1/2

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIGESTIVE SYSTEM NEUROENDOCRINE TUMOR UNRESECTABLE DIGESTIVE SYSTEM NEUROENDOCRINE NEOPLASM UNRESECTABLE DIGESTIVE SYSTEM NEUROENDOCRINE TUMOR G1 UNRESECTABLE DIGESTIVE SYSTEM NEUROENDOCRINE TUMOR G2

Contacts and locations

Locations

Emory University Hospital
RECRUITING

Atlanta, Georgia, 30322, United States
Emory University Hospital Midtown
RECRUITING

Atlanta, Georgia, 30308, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.